Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Swedish Orphan Biovitrum AB (GB:0MTD)
LSE:0MTD
RESEARCH TOOLSreports
Holding GB:0MTD?
Track your performance easily
0MTD Stock Chart & Stats
Day’s Rangekr0 - kr0
52-Week Rangekr237.00 - kr354.60
Previous Closekr298.6
Volume540.76K
Average Volume (3M)70.36K
Market Cap
kr102.03B
Enterprise Valuekr109.77B
Total Cash (Recent Filing)kr1.36B
Total Debt (Recent Filing)kr9.10B
Price to Earnings (P/E)29.0
Beta0.62
Next Earnings
Feb 05, 2025EPS Estimate
kr2.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.30
Shares OutstandingN/A
10 Day Avg. Volume63,010
30 Day Avg. Volume70,360
Standard Deviation0.09
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)4.16
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr347.00Price Target Upside16.21% Upside
Rating ConsensusHold
Number of Analyst Covering5
Swedish Orphan Biovitrum AB News
PremiumPre-Earnings
Is 0MTD a Buy, Before Earnings?
PremiumPre-Earnings
Is 0MTD a Buy, Before Earnings?
PremiumPre-Earnings
Is 0MTD a Buy, Before Earnings?
PremiumPre-Earnings
Is 0MTD a Buy, Before Earnings?
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.66% Mutual Funds
― Other Institutional Investors
91.90% Public Companies and
Individual Investors
0MTD FAQ
What was Swedish Orphan Biovitrum AB’s price range in the past 12 months?
Swedish Orphan Biovitrum AB lowest share price was kr237.00 and its highest was kr354.60 in the past 12 months.
What is Swedish Orphan Biovitrum AB’s market cap?
Currently, no data Available
When is Swedish Orphan Biovitrum AB’s upcoming earnings report date?
Swedish Orphan Biovitrum AB’s upcoming earnings report date is Feb 05, 2025 which is in 71 days.
How were Swedish Orphan Biovitrum AB’s earnings last quarter?
Swedish Orphan Biovitrum AB released its earnings results on Oct 24, 2024. The company reported kr4.27 earnings per share for the quarter, beating the consensus estimate of kr2.208 by kr2.062.
Is Swedish Orphan Biovitrum AB overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum AB’s price is currently Undervalued.
Does Swedish Orphan Biovitrum AB pay dividends?
Swedish Orphan Biovitrum AB does not currently pay dividends.
What is Swedish Orphan Biovitrum AB’s EPS estimate?
Swedish Orphan Biovitrum AB’s EPS estimate is kr2.9.
How many shares outstanding does Swedish Orphan Biovitrum AB have?
Swedish Orphan Biovitrum AB has 356,000,060 shares outstanding.
What happened to Swedish Orphan Biovitrum AB’s price movement after its last earnings report?
Swedish Orphan Biovitrum AB reported an EPS of kr4.27 in its last earnings report, beating expectations of kr2.208. Following the earnings report the stock price went up 3.284%.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum AB?
Currently, no hedge funds are holding shares in GB:0MTD
---
Swedish Orphan Biovitrum AB Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.01%
12-Months-Change
Fundamentals
Return on Equity
9.83%
Trailing 12-Months
Asset Growth
-4.47%
Trailing 12-Months
Company Description
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hemophilia, immunology, and hereditary conditions. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement development programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi recently acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition).
---
0MTD Stock 12 Month Forecast
Average Price Target
kr347.00
▲(16.21% Upside)
Technical Analysis
Best Analysts Covering 0MTD
1 Year
1 Year Success Rate
10/12 ratings generated profit
1 Year Average Return
+16.67%
reiterated a buy rating 26 days ago
Copying Alistair Campbell's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +16.67% per trade.
---